药通中国春季路演公司介绍 Part 1

Black Diamond Therapeutics 的核心策略针对广泛的肿瘤致癌突变家族，有潜力惠及治疗选择有限的大量患者群体。公司正在推进口服疗法的研发，旨在为患者提供更长、更健康、更积极的生活机会。其核心资产BDTX-1535在非小细胞肺癌中显示出持久的临床效果，并在胶质母细胞瘤中展现额外疗效。

Black Diamond Therapeutics’ MasterKey approach targets broad families of oncogenic mutations, with the potential to benefit large patient populations with limited treatment options. The company is advancing oral therapies designed to give patients the opportunity for a longer, healthier, active life. The Lead asset BDTX-1535 shows durable clinical responses in NSCLC, with additional opportunity in GBM.

ILDONG成立于1941年，于2016年在KOSPI上市。截至2024年3月26日，其市值超过3亿美元。该公司拥有广泛的产品线，涵盖慢性疾病、癌症治疗、心血管、抗生素、非处方药和消化治疗药物。该公司在2022年实现了5.48亿美元的销售额，并将销售额的20%用于研发工作，目前有30个项目在研。

ILDONG was founded in 1941 and listed on the KOSPI in 2016. As of March 26, 2024, its market capitalization exceeds $300 M. The company has a wide range of product lines covering chronic diseases, cancer treatment, cardiovascular, antibiotics, over-the-counter drugs, and digestive therapeutics. In 2022, the company achieved sales of $548 million and allocated 20% of its sales for research and development, currently managing 30 projects.

Aptamer Sciences 是适配体领域的全球领先公司。公司提供从早期诊断到疾病治疗的全方位适配体解决方案。早期多样性和生物稳定性不足限制了天然核苷酸的适配体的商业化进程，而改良核苷酸的引入显著增强了了适配体的成药性，为技术商业化奠定了基础。Aptamer Sciences 正努力构建适配体发现及创新产平应用的综合平台。

Aptamer Sciences is a global leading company in the field of aptamers. The company provides total aptamer solutions from early diagnosis to treatment of diseases. Natural nucleoside-based aptamers in the early days had limitations in commercialization due to the lack of diversity and biostability. However, since aptamers with significantly improved druggability using modified nucleosides were introduced, the technological foundation for commercialization has been laid. Aptamer Sciences is making efforts to build an integrated platform for aptamer discovery as well as the development of innovative products for application.

Kangstem Biotech采用逐步商业策略来优化其全球化新药物开发的成功率。Kangstem初衷是开发针对罕见和不可治愈疾病的干细胞治疗产品，并预备成为世界顶尖干细胞公司。依托公司特有的研发平台，公司计划开发二代药物，并成为全球化生物制药公司。

Kangstem Biotech employs a step-by-step business strategy to optimize its success rate in developing new global medicines. Established to develop stem cell therapeutic products for rare and incurable diseases, Kangstem aims to become the world’s top stem cell company, respected by customers and markets. Leveraging the company’s R&D technology, they plan to develop next-generation medicines and be recognized as a global biopharmaceutical company.

Chimeric Therapeutics通过发现、开发和商业化具有最具治愈潜力的细胞疗法，为更多癌症患者带来希望。该公司通过灵活的资产优化、创新的试验设计以及持续优化技术平台来寻找对患者治愈具有最大潜力的创新细胞疗法。

Chimeric Therapeutics’ mission is to bring that promise to life for more patients with cancer by discovering, developing and commercializing cell therapies with the most curative potential. The company focuses on identifying innovative cell therapies with the most curative potential for patients and drives cell therapy drug development with agile asset optimization, innovative trial design, and an unwavering focus on technical operations.

领泰生物专注于First-in-class/Best-in-class小分子创新药物的发现开发。基于团队丰富的研发经验和差异化战略，公司建立了目标蛋白泛素化和降解平台Nano-SPUD®，用于快速筛选和开发目标细胞内蛋白和E3连接酶，以及目标蛋白泛素化和降解平台Lyso-SPUD®，用于筛选和开发目标细胞外蛋白。

Leading Tac Pharma focuses on the discovery and development of First-in-class/Best-in-class small molecule innovative drug. Based on the team’s rich R&D experience and differentiation strategy, the company has established Nano-SPUD®, a target protein ubiquitination and degradation platform for the rapid screening and development of target intracellular proteins and E3 ligases, and Lyso-SPUD®, a target protein ubiquitination and degradation platform for the screening and development of target extracellular proteins.

Camurus 是一家总部位于瑞典的制药公司，致力于开发和商业化治疗严重和慢性疾病的长效创新药物。基于独特的FluidCrystal®药物递送技术和丰富的研发经验，公司开发出具有一流潜力的新药产品。Camurus 的临床管线布局包括依赖症、疼痛、癌症和内分泌疾病。产品管线内部开发与国际制药公司合作开发并行。

Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases. New medicinal products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies.

Renexxion, Inc.是一家总部位于美国的生物技术公司。该公司为胃肠道疾病患者提供创新口服药物Naronapride。主力产品Naronapride是处于后期阶段的潜在best-in-class候选，适用于上消化道和下消化道症状，并具有高度未满足的医疗需求。在科学研究已经表明Naronapride具有独特的血清素5HT4受体激动和多巴胺D2受体拮抗性能，这两者都是经临床验证的靶点。Naronapride的设计旨在最大程度减少身体吸收，并在肠腔内具有局部活性，从而潜在增强了药物疗效和安全性。迄今为止，药物已完成了四项临床二期研究并展示了积极的数据。

Renexxion, Inc. is a US based biotechnology company. The company committed to delivering innovative drugs to patients with a high unmet need in gastrointestinal disorders with its pipeline in a pill: Naronapride. The lead asset Naronapride is a late-stage, potential best-in-class drug candidate for indications in the upper and lower GI tract with high unmet medical needs.  In scientific studies naronapride has demonstrated that it possesses a unique combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties, both clinically validated targets.  Naronapride was designed to be minimally absorbable and locally active in the gut lumen to potentially enhance efficacy and safety. To date, four Phase-II studies have been completed and shown positive data.

默达生物是中国，乃至亚洲第一家在免疫代谢这个新兴领域深耕，以研发免疫代谢 first-in-class 原创药物的商业化公司。默达生物创始团队在免疫代谢这个新兴的科学领域深耕多年，其创始人从事相关生物基础理论研究近八年，一直致力于探索免疫细胞和营养物质新陈代谢之间互相调控的生物机制，突破性地发现可以通过调控免疫细胞的新陈代谢的活力来实现免疫系统功能调节的治疗策略。该治疗策略可针对和用于治疗由免疫系统和代谢系统紊乱造成的各类慢性疾病，包括自身免疫疾病，癌症，代谢疾病和衰老引起的各种慢性病。

META Pharmaceuticals Inc. is the first commercial company in China and Asia to develop innovative drugs in the emerging field of immunometabolism, which targets the metabolic pathways of immune cells. With a strong expertise in immunometabolism, the founders have spent years exploring the complex biological mechanisms that regulate immune cell metabolism and nutrient sensing. This rigorous research has led to a novel therapeutic strategy that modulates immune system function by manipulating the metabolic activity of immune cells. META Pharmaceuticals’ cutting-edge approach has enormous potential for treating a wide range of chronic diseases caused by immune and metabolic system disorders. These include autoimmune diseases, cancer, metabolic disorders, and various age-related chronic conditions. By harnessing the therapeutic strategy developed by the founding team, META Pharmaceuticals aims to provide effective treatments for patients suffering from these debilitating diseases.

领诺医药于2019年8月成立，在上海自由贸易试验区张江药谷有近1000平米的研发实验室和覆盖从概念到临床的研发团队。自主开发了独有的血液半衰期延长（长效）、穿越血脑屏障等专利技术，并基于相关平台技术开发针对严重罕见病的孤儿药，包括补体靶向的抗体、重组蛋白类药物。研发管线覆盖针对新靶点、新机制、新适应症的First-in-class（FIC）产品，以及平台技术赋能、针对成熟靶点的Best-in-class（BIC）产品。

Linno is dedicated to develop cutting-edge enabling technologies and novel therapeutic products to address major challenges in management of chronic human diseases. With proprietary Nano Brain-pass technology which enables blood-brain barrier-penetrating drug delivery for multiple forms of moieties, and next-generation pathway-selective complement inhibitors, Linno is working with partners to develop first- or best-of-class therapeutics, including orphan drugs for rare and devastating diseases.